A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale, which informs drug policies across Europe. The changes focus on addressing use and abuse separately, collecting input from a broader range of stakeholders, and targeting substance-specific experts for drug review panels.